First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study

First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study

Abstract Although first-line immunochemotherapy has improved prognosis for patients with advanced esophageal squamous cell carcinoma (ESCC), more effective strategies still require further investigation. This multi-center, phase II study (ClinicalTrials.gov NCT05013697) assessed the feasibility of b...

Full description

Saved in:
Bibliographic Details
Main Authors: Ning Li, Jin Xia, Xiaohui Gao, Jianwei Zhou, Yonggui Hong, Donghai Cui, Xuesong Zhao, Tao Wu, Yanzhen Guo, Junsheng Wang, Suxia Luo
Format: Article
Language:English
Published: Nature Publishing Group 2024-11-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-024-02008-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-024-02008-7

Similar Items